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We evaluated GenoType Mycobacteria Direct (GTMD), a novel commercial assay based on nucleic acid
sequence-based amplification technology, for the detection of Mycobacterium tuberculosis complex, M. avium, M.
intracellulare, M. kansasii, and M. malmoense directly from clinical specimens. A total of 134 respiratory and
extrapulmonary samples from 65 patients were processed. Sensitivity, specificity, positive predictive, and
negative predictive values for GTMD were 92, 100, 100, and 77%, respectively. The GMTD technique is useful,
reliable, and rapid when used during the normal routine of a clinical laboratory.
Worldwide, tuberculosis (TB) is one of the major causes of
death (7). The World Health Organization estimates that, an-
nually, 9 million inhabitants of the world develop tuberculosis
and that it is the cause of more than 2 million deaths (12). With
the introduction of molecular techniques for the identification
of mycobacteria from culture and the application of molecular
techniques for direct detection in clinical specimens, techno-
logical development in TB diagnosis has experienced a consid-
erable increase over the last few years (4, 9).
The aim of this study was to evaluate a recently commer-
cialized novel genetic assay, namely, GenoType Mycobacteria
Direct (GTMD) (Hain Lifescience GMBH, Nehren, Ger-
many), that is capable of detecting Mycobacterium tuberculosis
complex (MTBC) and four atypical mycobacterium species of
clinical interest and to compare the results with those of the
COBAS AMPLICOR MTB system (Roche Diagnostics).
The assay was performed by the Microbiology Service of
Reina Sofia University Hospital (Cordoba, Spain), together
with the Mycobacteria Reference Center (Faculty of Medicine,
Cordoba University, Cordoba, Spain). We analyzed 134 sam-
ples (100 sputa, 1 bronchoalveolar lavage, 4 bronchial aspirate,
4 pleural fluid, 13 adenopathy biopsy, 2 purulent exudate, 2
abscess, 1 feces, 2 ascitic fluid, 2 cephalorhachidian fluid, and
3 urine samples) from 65 patients suspected of having TB or
another type of mycobacteriosis. All samples, except those that
came from sterile compartments, were decontaminated by
treatment with N-acetylcysteine–4% NaOH and concentrated
by centrifugation. For microscopic study, the fixed prepara-
tions were stained with auramine-rhodamine and visualized
with a fluorescence microscope (magnification, 40). All pos-
itive and doubtful samples were processed and examined for
the detection of acid-fast bacilli with Ziehl-Neelsen staining.
After digestion, decontamination, and concentration, the sam-
ples were seeded in MGIT and Lowenstein-Jensen media ac-
cording to the manufacturer’s instructions (Becton Dickinson,
Sparks, MD). Two 500-l aliquots were removed for prepara-
tion and processing following the protocols of the molecular
techniques evaluated in our study, GenoType Mycobacteria Di-
rect and COBAS AMPLICOR MTB. All isolates grown in dif-
ferent culture media were identified by the GenoType Mycobac-
terium CM assay (Hain Lifescience GMBH, Nehren, Germany)
(11) or by AccuProbe hybridization probes (AccuProbe, Gen-
Probe, Inc., San Diego, CA).
GenoType Mycobacteria Direct. This is a novel commercial
assay based on the nucleic acid sequence-based amplification
(NASBA) and DNA strip techniques, allowing the 23S rRNA
amplification-based detection of MTBC, M. avium, M. intra-
cellulare, M. kansasii, and M. malmoense directly from decon-
taminated clinical specimens. This assay is divided in three
parts and was performed according to the manufacturer’s in-
structions.
The first part consists of the stabilization and RNA isolation
of decontaminated specimens using a capture method (mag-
netic bead capture probe). The process began with cellular
rupture: 300 l of inhibitory removing buffer was pipetted into
a 2-ml tube containing 500 l of decontaminated specimen.
After homogenizing, the mixture was centrifuged for 3 min at
12,000  g. The supernatant was removed, and the pellet was
resuspended with 100 l of RNA capture buffer. The sample
was then incubated at 95°C for 30 min, followed by immersion
in a preheated 60°C ultrasonic bath for 15 min. Subsequently,
10 l of magnetic beads was added to a mixture of 90 l of
internal control and the capture probe and 100 l of the pre-
viously obtained cellular lysate in a 0.5-ml tube. After vortex-
ing, a binding reaction was performed in a TwinCubator (Hain
Lifescience GMBH, Nehren, Germany) by using a program
with two steps of different incubation temperatures. In the first
step, the samples were incubated at 65° for 10 min; this was
followed by a second incubation step of 17 min at 25°C com-
bined with shaking at a frequency of 1,100 rpm. For washing,
the samples were transferred to a magnetic separator. After a
dark-colored precipitate formed (approximately 3 min), the
supernatant was removed, the magnetic bar of the magnetic
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separator was withdrawn, and the pellet was resuspended in
200 l of washing buffer. This washing process was performed
twice. After the second wash, 20 l of magnetic beads buffer
was added to the pellet, resulting in “loaded magnetic beads.”
The second part of the procedure comprised an isothermic
amplification of RNA by the NASBA method, in which there
is a mixture of primers/nucleotides labeled with biotin and a
mixture of enzymes: for each reaction, 30 l of primers/nucle-
otides labeled with biotin was added to a 0.5-ml tube and
mixed with 10 l of loaded magnetic beads. The sample was
covered with 20 to 30 l of liquid paraffin oil, and the tubes
were transferred to the TwinCubator. The process began with
a preliminary denaturation step, in which the temperature of
the samples was raised to 65°C for 8 min. Subsequently, the
samples were cooled to 41°C and the NASBA reaction was
started by adding 10 l of the previously reconstituted enzyme
mixture. The amplification process then commenced for a pe-
riod of 60 min.
Finally, in the third part of the process, reverse hybridization
of the amplified products was performed using an automated
system (Profiblot; Tecan, Maennedorf, Switzerland) (2, 11).
This machine allows the shaking, heating, and dispensing of
the reagents required for the hybridization reaction on mem-
brane strips. Once the strips were completely dry, they were
pasted on an evaluation sheet and interpreted using a reading
card, both provided by the manufacturer.
PCR COBAS AMPLICOR MTB. PCR COBAS AMPLICOR
MTB is a qualitative test for the detection of M. tuberculosis
complex microorganisms. The test technique was performed fol-
lowing the manufacturer’s instructions (3).
A total of 134 samples from 65 patients were processed.
Positive mycobacterium cultures were found in 97 samples.
The growth of M. tuberculosis complex was detected in 91
samples, whereas the other samples were positive for M. intra-
cellulare (1 sample), M. malmoense (1 sample), M. kansasii (2
samples), and M. avium (2 samples). The GenoType Mycobac-
teria Direct assay detected a total of 99 positive responses from
different types of samples. The GTMD assay detected 87 spec-
imens with a positive culture and 12 specimens with a negative
culture. Compared to results from culture, this indicates a sensi-
tivity and specificity of the GenoType Mycobacteria Direct assay
of 89 and 67%, respectively. The COBAS AMPLICOR MTB
system that amplifies DNA of only M. tuberculosis complex
detected 92 positive samples, 11 of which had been negative
in mycobacterium cultures. Compared to those from cul-
ture, these results indicate a sensitivity and specificity of the
COBAS AMPLICOR MTB of 83 and 70%, respectively. These
values increased to 89 and 70%, respectively, when samples
with only MTBC isolation were considered.
Discrepant results (positive results obtained with GenoType
Mycobacteria Direct and COBAS AMPLICOR MTB, but a
negative culture) were considered true positive when the pa-
tients suspected of having active pulmonary tuberculosis or
another type of mycobacteriosis had, after a review of their
clinical histories, responded to the antituberculous treatment
or exhibited positive mycobacterium cultures in specimens ob-
tained during the study period (1, 8). In this study, 12 samples
from 7 patients with negative cultures were positive by at least
one of the amplification techniques for MTBC and 11 were
positive by both methods. Five of the seven patients in the
discrepant panel had other positive cultures for mycobacteria
in the study period as well as clinical signs of disease and
responded to antituberculous treatment. The other two pa-
tients had clear signs of tuberculosis and responded to the
antituberculous treatment. Consequently, these 12 samples
were considered true positives, increasing the sensitivity and
specificity of the GTMD technique to 92 and 100%, respec-
tively, and that of COBAS AMPLICOR MTB to 91 and 100%,
respectively, for the samples of patients with MTBC isolations
(Table 1). Results from the GenoType Mycobacteria Direct
assay were negative for eight specimens with positive culture.
Positive microscopy was found in only one of these specimens.
These samples were taken from seven patients who were not
receiving antituberculous treatment when the specimens were
taken. The growing time of these samples in liquid medium
was between 6 and 25 days, with a median of 14 days. Both
amplification assays were made from the same specimen and at
the same time. GenoType Mycobacteria Direct detected all six
atypical pathogen mycobacterium isolations collected during
this study, corresponding to one M. intracellulare, one M. mal-
moense, and 2 isolations each of M. avium and M. kansasii
(Table 2).
The new genetic GenoType Mycobacteria Direct assay is
based on NASBA technology described for the first time at the
beginning of the 1990s by Kievits et al. (10). Since then, several
advances and improvements of this process have been reported
(5, 6) that have been used in a multitude of assays for the
amplification of viral, bacterial, or parasitic RNA. A charac-
teristic of this technology is its capacity for detecting and am-
plifying RNA. In our study, GTMD detected samples with a
count of less than 10 bacilli per 100 fields in the auramine-
rhodamine staining. This new technique includes a laborious
TABLE 1. Results for sensitivity, specificity, PPV, and NPV of the genetic assays used to detect MTBCa
Technique and result
No. of samples froma:
Sensitivity (%) Specificity (%) PPV (%) NPV (%)Tuberculosis
patients (n  101)
Nontuberculosis
patients (n  27)
GenoType Mycobacteria Direct
Positive 93 0 92 100 100 77.1
Negative 8 27
COBAS AMPLICOR MTB
Positive 92 0 91 100 100 64.3
Negative 9 27
a The total number of samples was 128.
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extraction process and requires more manipulation than does
the COBAS AMPLICOR MTB system, which is more auto-
mated. Both assays take about 5 h to perform. The direct cost
of the GenoType Mycobacteria Direct assay is approximately
50 Euros, whereas that of COBAS AMPLICOR MTB is about
30 Euros. The detection of the amplified product with the
COBAS AMPLICOR MTB system is performed with spectro-
photometry reading, whereas GenoType Mycobacteria Direct
uses reverse hybridization technology of the amplified product
on membrane strips (2). The visualization of the bands on the
strips is more objective and interpretation is quick and easy.
The main difference in favor of the new GenoType Myco-
bacteria Direct assay is its ability to simultaneously detect five
mycobacterium species of clinical interest directly from clinical
specimens, thus eliminating the necessity of waiting for the
culture results. COBAS AMPLICOR also offers diagnostic
assays for the detection of M. avium and M. intracellulare but
not for M. kansasii and M. malmoense. Both assays harbor an
internal amplification control that allows the detection of the
presence of inhibitors in the sample. For the GenoType My-
cobacteria Direct assay, the absence of the so-called amplifi-
cation control band on the membrane strip is indicative of the
presence of inhibitors in case none of the species-specific
bands is visible. In our study, we detected only two samples
with inhibitors for the GenoType Mycobacteria Direct assay,
whereas we detected three inhibited samples with the COBAS
AMPLICOR. In the first test of this novel assay, conducted
with patients who were not treated or who received antituber-
culous treatment for fewer than 7 days, the sensitivity and
specificity were 87.5 and 100%, respectively (M. Weizenegger,
personal communication). These results are slightly inferior to
ours and were presented at the 25th Annual Congress of the
European Society of Mycobacteriology in 2004.
In conclusion, the GenoType Mycobacteria Direct is an easy
interpretable assay, which is relatively fast, as results can be
obtained within one working day. It is very reliable, as we
obtained values for sensitivity and specificity of 92 and 100,
respectively, and a positive predictive value (PPV) and a neg-
ative predictive value (NPV) of 100 and 77%, respectively.
Moreover, GTMD has the advantage of being able to detect
various species of mycobacterial pathogens in one assay and
from the same clinical sample.
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Biopsy (4) ....................................................M. tuberculosis complex (3)
M. intracellulare (1)
Bronchial aspirate (2) ................................M. tuberculosis complex (2)
Abscess (1) ..................................................M. tuberculosis complex (1)
Feces (1) ......................................................M. tuberculosis complex (1)
VOL. 44, 2006 NOTES 3027
